Your browser is no longer supported. Please, upgrade your browser.
Settings
TCRX [NASD]
TScan Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.42 Insider Own5.90% Shs Outstand24.46M Perf Week-13.57%
Market Cap165.11M Forward P/E- EPS next Y-2.17 Insider Trans1.03% Shs Float8.98M Perf Month0.30%
Income-33.60M PEG- EPS next Q-0.66 Inst Own42.40% Short Float1.03% Perf Quarter-32.57%
Sales6.00M P/S27.52 EPS this Y-91.30% Inst Trans332.12% Short Ratio0.75 Perf Half Y-
Book/sh- P/B- EPS next Y76.70% ROA- Target Price- Perf Year-
Cash/sh4.34 P/C1.55 EPS next 5Y- ROE- 52W Range6.06 - 14.71 Perf YTD-35.71%
Dividend- P/FCF- EPS past 5Y- ROI61.70% 52W High-54.11% Beta-
Dividend %- Quick Ratio5.30 Sales past 5Y- Gross Margin- 52W Low11.39% ATR0.65
Employees73 Current Ratio5.30 Sales Q/Q- Oper. Margin- RSI (14)35.73 Volatility11.56% 8.67%
OptionableNo Debt/Eq- EPS Q/Q-92.80% Profit Margin- Rel Volume0.77 Prev Close6.89
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume123.85K Price6.75
Recom1.70 SMA20-10.76% SMA50-22.72% SMA200-25.24% Volume95,086 Change-2.03%
Oct-15-21 10:56AM  
Oct-05-21 07:00AM  
Sep-28-21 07:00AM  
Sep-09-21 04:05PM  
Sep-02-21 07:00AM  
Aug-19-21 07:00AM  
Aug-16-21 09:58AM  
Jul-15-21 06:59PM  
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on developing a pipeline of T cell receptor-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, and TSC-203 for the treatment of solid tumors. The company has a collaboration and license agreement with Novartis Institutes for Biomedical Research, Inc. to discover and develop novel TCR-T therapies. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ZDRAVESKI ZORANChief Legal OfficerSep 23Buy7.484,71635,2554,716Sep 27 05:22 PM
Silver Brian M.Chief Financial OfficerSep 21Buy6.325,00031,58511,885Sep 22 06:51 PM
MacBeath GavinChief Scientific OfficerSep 21Buy6.195735349,767Sep 22 06:48 PM
MacBeath GavinChief Scientific OfficerSep 20Buy6.224,94330,74449,710Sep 22 06:48 PM